Daily Briefing – May 16: Friday risk-off reset, Ondas drone-defense momentum, Beam earnings miss, Intuitive Machines backlog and biotech catalyst calendar shape the weekend watchlist
The May 16 setup is a weekend reset after a risk-off Friday. U.S. equities pulled back from recent record territory as higher oil prices, rising Treasury yields and inflation worries hit growth and small-cap appetite, with the Russell 2000 under heavier pressure than the major large-cap indexes. That matters for this briefing because many of the most active Merlintrader lanes — drones, space, biotech, cannabis, small-cap AI and speculative defense technology — are rate-sensitive and liquidity-sensitive. Ondas remains one of the clearest single-stock execution stories after reporting record Q1 2026 revenue of $50.1 million, raising its full-year 2026 revenue forecast to at least $390 million and highlighting a larger backlog. Intuitive Machines remains in post-earnings digestion after record quarterly revenue, positive adjusted EBITDA, record quarter-end backlog of $1.1 billion and reaffirmed 2026 revenue guidance, while traders continue to judge whether space-infrastructure enthusiasm can convert into clean delivery. Beam Global has moved from “after-close event” to reported earnings: Q1 revenue fell to $3.1 million, backlog rose to $9.0 million, and management said Q2 revenue through the release date had already exceeded total Q1 revenue. Biotech remains catalyst-heavy, with Cingulate, Unicycive, Capricor, INOVIO and Zymeworks still giving traders a packed FDA calendar from late May into Q4. Cannabis also remains policy-sensitive ahead of the broader marijuana rescheduling hearing scheduled to begin June 29, 2026 at 9:00 a.m. ET.
- ONDS— Ondas remains the clearest drone-defense execution story after record Q1 2026 revenue of $50.1 million and a raised full-year 2026 revenue forecast of at least $390 millionDrones
- LUNR— Intuitive Machines is in post-earnings digestion after record quarterly revenue, positive adjusted EBITDA, record quarter-end backlog of $1.1 billion and reaffirmed 2026 revenue guidanceSpace
- BEEM— Beam Global reported Q1 2026 revenue of $3.1 million, down 51% year over year, while backlog increased to $9.0 million and Q2 revenue through the release date already exceeded total Q1 revenueEarnings
- ALT— Altimmune remains active after Q1 results and a strengthened cash position, with the pemvidutide story still tied to MASH, alcohol use disorder, alcohol-associated liver disease and development-spending disciplineBiotech
- CELC— Celcuity stays on the oncology watchlist after Q1 results showed elevated development spending and a larger loss profile as the company advances its late-stage clinical strategyOncology
- UNCY— Unicycive remains one of the closest renal/metabolic FDA events, with the OLC NDA resubmission carrying a June 29, 2026 PDUFA target action datePDUFA
- CAPR— Capricor remains under FDA review for deramiocel with an August 22, 2026 PDUFA date, keeping labeling, manufacturing readiness and launch preparation in focusPDUFA
- INO— INOVIO remains on the late-2026 regulatory watchlist with INO-3107 under FDA review and an October 30, 2026 PDUFA datePDUFA
- CING— Cingulate stays on the near-term FDA calendar with the May 31, 2026 PDUFA date for CTx-1301 keeping ADHD regulatory risk, labeling and financing pressure in focusFDA
- NVDA— Nvidia becomes the key large-cap AI event for the coming week, with traders watching whether earnings can defend the broader AI and semiconductor leadership trade after Friday’s pullbackSemis
- Friday changed the tone— U.S. indexes fell from recent highs as rising oil prices, higher yields and inflation worries hit risk appetite, with small caps under heavier pressure than large capsMarket
- Rate-sensitive baskets need caution— Biotech, small-cap space, AI software, cannabis and clean-energy names remain more exposed to higher yields, funding risk and liquidity rotationRates
- Drone-defense momentum remains alive— ONDS, RCAT, KTOS and AVAV remain tied to battlefield relevance, counter-UAS demand, funded orders and whether fast revenue growth can translate into cleaner marginsDefense
- Space stocks are in execution mode— LUNR, RKLB, RDW, BKSY and PL are being judged on backlog quality, revenue conversion, cash discipline and whether major space-AI headlines can become real contractsSpace
- PDUFA calendar is crowded— CING, UNCY, CAPR, ZYME and INO keep FDA timing at the center of biotech trading as decision windows stretch from late May through Q4 2026FDA
- Commercial biotech matters— OMER, LQDA and other launch-stage names keep the market focused on real product uptake, net sales quality, gross-to-net dynamics and whether launches can support valuationsBiotech
- AI hardware remains central— NVDA, AMD, AVGO, ARM, MU and AMAT remain tied to data-center demand, AI capex, China/trade headlines, valuation and next week’s earnings reactionSemis
- Cannabis policy remains live— The broader marijuana rescheduling hearing is scheduled to begin June 29, 2026, keeping TLRY, CGC, CRON, MSOS and IIPR on watchCannabis
Run-Up Biotech Masterclass
Learn how to read biotech catalysts, trial results and FDA decisions with a practical framework.
OpenBiotech Catalyst Calendar
Track FDA events, clinical readouts and biotech catalysts with a practical event-driven tool.
Open ArchiveBrowse the Blog & Archive
Explore articles, biotech deep dives, market notes, reports and archived sector content.
Open Reality CheckBiotech Trading Without the Fairy Tales
A grounded piece on risk, catalysts, dilution, volatility and biotech trading reality.
Open 2026 WatchlistThe New Era – Space, Defense & AI
A thematic watchlist built around military spending, strategic technology and AI-linked trends.
Open BriefingSPACE AI DEFENCE
A thematic briefing at the intersection of defense, space infrastructure and AI.
Open Top ListTop 10 Defense-Tech Stocks to Watch
A focused list built around defense technology, drones and strategic systems.
Open Top ListTop 5 U.S. Airlines Watchlist
A practical watchlist for pricing power, fuel sensitivity, travel demand and macro tone.
Open Top ListTop 5 Cruise Lines Watchlist
A leisure-focused list centered on major cruise operators and pricing-driven sentiment.
Open- Microbot Medical (Nasdaq: $MBOT): First LIBERTY Revenue, Real Doctors and the Small-Cap Robotics Test
- Viral Threats, Liver Fibrosis and Muscle Regeneration: $TRAW, $GALT and $MSLE Add Another Layer to the May 15 Biotech Tape
- Regulatory Paths, PDUFA Risk and Pivotal Oncology: $ATYR, $BTAI and $MBRX After the May 15 Updates
- Alzheimer’s, RAS Oncology and iNKT Cell Therapy: $ANVS, $IMRX and $INKT Enter the May 15 Biotech Watchlist
- Clinical Signals, Commercial Execution and Regulatory Paths: $TNYA, $SPRY and $BCDA After the May 15 Updates
- Innate Pharma (Nasdaq: $IPHA): Cancer Immunotherapy, PACIFIC-9, Lacutamab and the 2026 Catalyst Window
- Cingulate Inc. (Nasdaq: $CING): Q1 Cash Build, Commercial Readiness and the Final Stretch Toward the May 31 FDA Catalyst
- Three Biotech Earnings Reports, Three Different Catalyst Stories: Gene Therapy, Autoimmune Cell Therapy and Oncology in Focus — $RGNX, $CABA, $KPTI
- Three Biotech Earnings Stories Moving in Different Directions: $PGEN, $AQST and $ALLO
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and sector rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 to get 10% OFF your first paid period.
No credit card required to start. Apply SAVE10 when upgrading.
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with professional charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day and swing traders.
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
AI usage disclosure
This report has been prepared using a human + AI workflow. Drafting, editing and data organization are supported by generative AI tools, such as large language models provided by third parties, based on prompts and instructions defined by the author. All sources used are public, and the final selection of data, checks, opinions and conclusions remains with the author, who takes full responsibility for the content.
If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs, so the content can remain independent and freely accessible.
Biotech Catalyst Calendar
For a broader and continuously updated view of upcoming biotech catalysts — PDUFA dates, major clinical readouts, regulatory events and key conferences — you can visit the dedicated calendar on Merlintrader.